Discovery of Inhibitors of PTH-Wnt Signaling Synergy in Bone Cells
Department of Health and Human Services
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
DISCOVERYBIOMED, Inc., 1500 1ST AVE N, UNIT 37, BIRMINGHAM, AL, 35203
Socially and Economically Disadvantaged:
AbstractDESCRIPTION (provided by applicant): Project Summary Description Title: Discovery of Inhibitors of PTH-Wnt Signaling Synergy in Bone Cells. Osteoporosis is a growing problem in the aged and an unfortunately large disease market and burden to the healthcare industry. This debilitating disease costs 18 billion in healthcare costs annually in the US and affects 10 million people in the US and an estimated 100 million worldwide. Brittle bone disease is expected to increase in incidence in the years to come due to an aging US and worldwide population. DiscoveryBioMed, Inc., the University of Alabama at Birmingham (UAB) Research Foundation, and Dr. Xu Cao (a world renowned bone cell signaling researcher previously with UAB and currently with Johns Hopkins) has forged a research collaboration to discover small molecule therapeutics that prevent osteoporosis. DBM has developed a light-based assay to find inhibitors of synergistic parathyroid hormone (PTH) and Wnt signaling pathways. DBM seeks to multiplex this high-throughput screening (HTS) friendly bioassay with additional light-based endpoints in cellular lysates and in the supernatant collected before cell lysis to monitor a series of endpoints relevant to osteoporosis drug discovery. Most importantly, this screening program utilizes a mammalian bone cell line as the biologically relevant cellular platform. Milestone 1 of this program seeks to fully design and optimize each individually light-based assay for each desired biological endpoint. Milestone 2 seeks to multiplex each individual assay into one powerful primary HTS bioassay. Milestone 3 seeks to screen the first 20,000 small molecules from a diverse set of synthetic organic compounds and natural product-derived phytochemicals. As a transition to planned Phase 2 research, DBM will assess hit-to-lead compounds early and often with cheminformatics tools to identify commonality in structure among the hit small molecules. This process allows parallel targeted work on lead compounds of interest already identified, while random screening proceeds. DBM will apply its core principles of drug discovery to this program that include: (a) screening on a biologically relevant cell platform (i.e., bone cells); (b) screening with both targeted and phenotypic intent and endpoints; (c) screening each test small molecule in triplicate to provide biostatistical power to the primary HTS experiment; and (d) assessing multiple high-content endpoints in primary HTS bioassay and in carefully scripted secondary validation experiments with Dr. Cao's research group. Based on the work accomplished thus far, DBM anticipates a strong outcome from this osteoporosis drug discovery program. PUBLIC HEALTH RELEVANCE: Public Health Relevance Statement Osteoporosis is a billion burden to the healthcare industry, with 10 million people affected in the US and an estimated 100 million affected worldwide. Brittle bone disease is expected to increase in incidence in the years to come due to an aging US and worldwide population. DiscoveryBioMed, Inc., the UAB Research Foundation, and Dr. Xu Cao and coworkers from Johns Hopkins have formed a triangular research collaboration to find new small molecule therapeutics to control and cure osteoporosis that work at the cellular and molecular level within bone tissue.
* information listed above is at the time of submission.